Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)
A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
Sponsor: National Cancer Institute (NCI)
This PHASE2 trial investigates Advanced Lung Non-Squamous Non-Small Cell Carcinoma and Recurrent Lung Non-Squamous Non-Small Cell Carcinoma and is currently completed. National Cancer Institute (NCI) leads this study, which shows 14 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Oct 2024 — Sep 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 9 earlier versions
-
May 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2023 — May 2023 [monthly]
Active Not Recruiting PHASE2
-
Feb 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE2
-
Jun 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE2
-
Oct 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
May 2020 — Sep 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2019 — May 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .